• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 6-K filed by Stevanato Group S.p.A.

    5/2/25 4:05:48 PM ET
    $STVN
    Medical/Dental Instruments
    Health Care
    Get the next $STVN alert in real time by email
    6-K 1 d130192d6k.htm 6-K 6-K
     
     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    FORM 6-K

     

     

    REPORT OF FOREIGN PRIVATE ISSUER

    PURSUANT TO RULE 13a-16 OR 15d-16

    UNDER THE SECURITIES EXCHANGE ACT OF 1934

    For the month of April 2025

    Commission File Number: 001-40618

     

     

    Stevanato Group S.p.A.

    (Translation of registrant’s name into English)

     

     

    Via Molinella 17

    35017 Piombino Dese – Padua

    Italy

    (Address of principal executive office)

     

     

    Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

    Form 20-F ☒   Form 40-F ☐

     

     
     


    EXPLANATORY NOTE

    This report on Form 6-K (the “report”) and the exhibits to this report contain certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that reflect the current views of Stevanato Group S.p.A. (“we”, “our”, “us”, “Stevanato Group”, the “Company” and, together with its subsidiaries, the “Group”). These forward-looking statements include, or may include, words such as “anticipate,” “assumes,” “believe,” “derive,” “drive,” “estimated,” “forecast,” “foreseeable,” “future,” “growing,” “increase,” “may,” “plan,” “potential,” “remain,” “to be,” “will,” “would,” and other similar terminology. Forward-looking statements contained in this report include, but are not limited to, statements about: our future financial performance, including our revenue, operating expenses and our ability to maintain profitability and operational and commercial capabilities; our expectations regarding the development of our industry and the competitive environment in which we operate; the expansion of our plants and sites, and our expectations related to our capacity expansion; the global supply chain and our committed orders; customer demand and customers’ ability to destock higher inventories accumulated during the COVID-19 pandemic; the success of our initiatives to optimize the industrial footprint, harmonize processes and enhance supply chain and logistics strategies; our geographical and industrial footprint; and our goals, strategies and investment plans. These statements are neither promises nor guarantees but involve known and unknown risks, uncertainties and other important factors and circumstances that may cause Stevanato Group’s actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including conditions in the U.S. capital markets, negative global economic conditions, inflation, the impact of the conflict between Russia and Ukraine, the evolving events in Israel and Gaza, supply chain and logistical challenges and other negative developments in Stevanato Group’s business or unfavorable legislative or regulatory developments. The following are some of the factors that could cause our actual results to differ materially from those expressed in or underlying our forward-looking statements: (i) our product offerings are highly complex, and, if our products do not satisfy applicable quality criteria, specifications and performance standards, we could experience lost sales, delayed or reduced market acceptance of our products, increased costs and damage to our reputation; (ii) we must develop new products and enhance existing products, adapt to significant technological and innovative changes and respond to introductions of new products by competitors to remain competitive; (iii) if we fail to maintain and enhance our brand and reputation, our business, results of operations and prospects may be materially and adversely affected; (iv) we are highly dependent on our management and employees. Competition for our employees is intense, and we may not be able to attract and retain the highly skilled employees that we need to support our business and our intended future growth; (v) our business, financial condition and results of operations depend upon maintaining our relationships with suppliers and service providers; (vi) our business, financial condition and results of operations depend upon the availability and price of high-quality materials and energy supply and our ability to contain production costs; (vii) significant interruptions in our operations could harm our business, financial condition and results of operations; (viii) as a consequence of the COVID-19 pandemic, sales of syringes and vials to and for vaccination programs globally increased resulting in a revenue growth acceleration. The demand for such products may shrink, as the need for COVID-19 related solutions continue to decline; (ix) our manufacturing facilities are subject to operating hazards which may lead to production curtailments or shutdowns and have an adverse effect on our business, results of operations, financial condition or cash flows; (x) our business, financial condition and results of operations may be impacted by our ability to successfully expand capacity to meet customer demand; (xi) the loss of a significant number of customers or a reduction in orders from a significant number of customers, including through destocking initiatives or lack of transparency of our products held by customers, could reduce our sales and harm our financial performance; (xii) we may face significant competition in implementing our strategies for revenue growth in light of actions taken by our competitors; (xiii) our global operations are subject to international market risks that may have a material effect on our liquidity, financial condition, results of operations and cash flows; (xiv) we are required to comply with a wide variety of laws and regulations and are subject to regulation by various federal, state and foreign agencies; (xv) given the relevance of our activities in the healthcare sector, investments by non-Italian entities in the Company, as well as certain asset disposals by the Company, may be subject to the prior authorization of the Italian Government (so called “golden powers”); (xvi) if relations between China and the U.S. deteriorate (including in connection with the current trade policy of the U.S.


    government), our business in the U.S. and China could be materially and adversely affected; (xvii) the U.S. government recently imposed tariffs on certain products manufactured in several jurisdictions, including China and the European Union, and has made announcements regarding the potential imposition of tariffs on other jurisdictions. Such tariffs as well as other trade policies that the U.S. government may implement in the future and the restrictive trade measures that other countries may adopt in response thereto, could adversely affect our business by making more difficult or costly to trade goods between different jurisdictions; (xviii) cyber security risks and the failure to maintain the confidentiality, integrity and availability of our computer hardware, software and internet applications and related tools and functions, could result in damage to our reputation, data integrity and/or subject us to costs, fines or lawsuits under data privacy or other laws or contractual requirements; (xix) our trade secrets may be misappropriated or disclosed, and confidentiality agreements with directors, employees and third parties may not adequately prevent disclosure of trade secrets and protect other proprietary information; (xx) if we are unable to obtain and maintain patent protection for our technology, products and potential products, or if the scope of the patent protection obtained is not sufficiently broad, we may not be able to compete effectively in our markets; (xxi) we depend in part on proprietary technology licensed from others, and if we lose our existing licenses or are unable to acquire or license additional proprietary rights from third parties, we may not be able to continue developing our potential products; and (xxii) we are obligated to maintain proper and effective internal controls over financial reporting. Our internal controls were not effective for the year ended December 31, 2024, and in the future may not be determined to be effective, which may adversely affect investor confidence in us and, as a result, the value of our ordinary shares. This list is not exhaustive. We caution you therefore against relying on these forward-looking statements, and we qualify all of our forward-looking statements by these cautionary statements.

    These forward-looking statements speak only as at their dates. The Company undertakes no obligation to update any forward-looking statement or statements to reflect events or circumstances after the date on which such statement is made or to reflect the occurrence of unanticipated events. New factors emerge from time to time, and it is not possible to predict all of these factors. Further, the Company cannot assess the impact of each such factor on our business or the extent to which any factor, or combination of factors, may cause actual results to be materially different from those contained in any forward-looking statements.

    For a description of certain additional factors that could cause the Company’s future results to differ from those expressed in any such forward-looking statements, refer to the risk factors discussed in our Annual Report on Form 20-F for the year ended December 31, 2024 filed with the U.S. Securities and Exchange Commission on March 6, 2025.


    EXHIBIT INDEX

    The following exhibits are furnished as part of this Form 6-K:

     

    Exhibit

      

    Description

    99.1    Notice of Shareholders’ Meeting dated April 11, 2025
    99.2    Explanatory Report on the items on the agenda – Shareholders’ Meeting dated April 29, 2025
    99.3    Sustainability Report for the financial year 2024
    99.4    Report of the Audit Committee on the activities carried out in the financial year 2024
    99.5    Report of the Nominating and Corporate Governance Committee for the financial year 2024
    99.6    Report of the Compensation Committee on the Company’s Remuneration Policy and Practices for the financial year 2024
    99.7    Substantiated Proposal of the Audit Committee
    99.8    Slate of Candidate Directors


    SIGNATURES

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

    Date: May 2, 2025

     

    Stevanato Group S.p.A.
    By:  

    /s/ Franco Stevanato

    Name:   Franco Stevanato
    Title:   Chief Executive Officer
    Get the next $STVN alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $STVN

    DatePrice TargetRatingAnalyst
    12/2/2025$24.00Equal-Weight
    Morgan Stanley
    12/13/2024$28.00Outperform
    Wolfe Research
    12/3/2024$23.00Equal-Weight
    Morgan Stanley
    4/22/2024Outperform
    Exane BNP Paribas
    11/1/2023$39.00 → $29.00Buy → Hold
    Jefferies
    9/26/2023$33.00Overweight
    Stephens
    9/19/2023Market Outperform
    CJS Securities
    8/24/2023$34.00Overweight → Equal-Weight
    Morgan Stanley
    More analyst ratings

    $STVN
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by Stevanato Group S.p.A.

    SCHEDULE 13G/A - Stevanato Group S.p.A. (0001849853) (Subject)

    2/3/26 2:00:05 PM ET
    $STVN
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Stevanato Group S.p.A.

    SCHEDULE 13G/A - Stevanato Group S.p.A. (0001849853) (Subject)

    1/9/26 9:23:31 AM ET
    $STVN
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Stevanato Group S.p.A.

    SCHEDULE 13G/A - Stevanato Group S.p.A. (0001849853) (Subject)

    12/3/25 2:38:08 PM ET
    $STVN
    Medical/Dental Instruments
    Health Care

    $STVN
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Stevanato Group Reports Revenue of €303.2 Million for the Third Quarter of 2025

    Company delivers 9% revenue growth, record revenue from high-value solutions, expanded margins, and maintains fiscal year 2025 guidance Stevanato Group S.p.A. (NYSE:STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, today announced its financial results for the third quarter of 2025. Third Quarter 2025 Highlights (comparisons to prior-year period) Revenue increased 9% (11% on a constant currency basis) to €303.2 million. High-value solutions represented a record 49% of total revenue. Gross profit margin increased 240 basis points to 29.2%. Diluted earnings per share were

    11/6/25 6:30:00 AM ET
    $STVN
    Medical/Dental Instruments
    Health Care

    Stevanato Group to Participate in Upcoming Investor Conferences

    Stevanato Group S.p.A. (NYSE:STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, today announced that it will participate in two upcoming investor conferences. Monday, November 17, 2025, at 8:40 a.m. ET - The 7th Annual Wolfe Research Healthcare Conference in New York City Wednesday, November 19, 2025, at 11:00 a.m. GMT - The Jefferies Global Healthcare Conference in London A live webcast of each event will be available on the Company's website at www.stevanatogroup.com under the "Investors" section. Replays will remain available for approximately 90 days after each event.

    10/31/25 7:30:00 AM ET
    $STVN
    Medical/Dental Instruments
    Health Care

    Stevanato Group to Report Third Quarter 2025 Financial Results on November 6, 2025

    Stevanato Group S.p.A. (NYSE:STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, announced today that it will issue financial results for the third quarter of 2025 on Thursday, November 6, 2025, at 6:30 a.m. (ET). Conference call and webcast: The Company will host a conference call and webcast at 8:30 a.m. (ET) on Thursday, November 6, 2025, to discuss financial results. During the call, management will refer to a slide presentation which will be available on the morning of the call on the "Financial Results" page under the Company's Investor Relations section of its website. Pr

    10/22/25 6:30:00 AM ET
    $STVN
    Medical/Dental Instruments
    Health Care

    $STVN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Morgan Stanley resumed coverage on Stevanato Group S.p.A. with a new price target

    Morgan Stanley resumed coverage of Stevanato Group S.p.A. with a rating of Equal-Weight and set a new price target of $24.00

    12/2/25 8:34:50 AM ET
    $STVN
    Medical/Dental Instruments
    Health Care

    Wolfe Research initiated coverage on Stevanato Group S.p.A. with a new price target

    Wolfe Research initiated coverage of Stevanato Group S.p.A. with a rating of Outperform and set a new price target of $28.00

    12/13/24 8:24:13 AM ET
    $STVN
    Medical/Dental Instruments
    Health Care

    Morgan Stanley resumed coverage on Stevanato Group S.p.A. with a new price target

    Morgan Stanley resumed coverage of Stevanato Group S.p.A. with a rating of Equal-Weight and set a new price target of $23.00

    12/3/24 8:38:45 AM ET
    $STVN
    Medical/Dental Instruments
    Health Care

    $STVN
    Leadership Updates

    Live Leadership Updates

    View All

    Stevanato Group Announces Results of Annual General Meeting

    -All Resolutions Proposed to Shareholders Passed- Stevanato Group S.p.A. (NYSE:STVN), a leading global provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries today announced that all resolutions proposed to the Shareholders at the Annual General Meeting of Shareholders ("AGM") held virtually on May 22, 2024, have passed. Details of the resolutions submitted to, and approved by, the AGM are included in the explanatory report prepared by the Board of Directors of the Company, which is available on the Company's corporate website at https://ir.stevanatogroup.com/. Shareholders approved, among other things, th

    5/24/24 4:10:00 PM ET
    $STVN
    Medical/Dental Instruments
    Health Care

    Stevanato Group appoints Ugo Gay as Chief Operations Officer

    Strengthening corporate leadership aims to drive operational efficiencies and standardization of global processes. Stevanato Group S.p.A. (NYSE:STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life science industries, today announced the appointment of Ugo Gay as its new Chief Operations Officer (COO). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240404727049/en/Ugo Gay appointed as Chief Operations Officer of Stevanato Group (Photo: Business Wire) The addition of Ugo Gay underscores Stevanato Group's unwavering commitment to driving opera

    4/4/24 8:00:00 AM ET
    $STVN
    Medical/Dental Instruments
    Health Care

    Stevanato Group Appoints Riccardo Butta as President, Americas

    The appointment bolsters company's commitment to growth in the region Stevanato Group, a global provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries, today announced the appointment of Riccardo Butta to the role of President, Americas. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220202005514/en/Riccardo Butta (Photo: Business Wire) The appointment of a dedicated executive to lead the Company's long-term strategy in the Americas is indicative of the growing regional demand trends and the Company's commitment to broaden its footprint, accelerate i

    2/2/22 8:30:00 AM ET
    $STVN
    Medical/Dental Instruments
    Health Care

    $STVN
    Financials

    Live finance-specific insights

    View All

    Stevanato Group Reports Revenue of €303.2 Million for the Third Quarter of 2025

    Company delivers 9% revenue growth, record revenue from high-value solutions, expanded margins, and maintains fiscal year 2025 guidance Stevanato Group S.p.A. (NYSE:STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, today announced its financial results for the third quarter of 2025. Third Quarter 2025 Highlights (comparisons to prior-year period) Revenue increased 9% (11% on a constant currency basis) to €303.2 million. High-value solutions represented a record 49% of total revenue. Gross profit margin increased 240 basis points to 29.2%. Diluted earnings per share were

    11/6/25 6:30:00 AM ET
    $STVN
    Medical/Dental Instruments
    Health Care

    Stevanato Group to Report Third Quarter 2025 Financial Results on November 6, 2025

    Stevanato Group S.p.A. (NYSE:STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, announced today that it will issue financial results for the third quarter of 2025 on Thursday, November 6, 2025, at 6:30 a.m. (ET). Conference call and webcast: The Company will host a conference call and webcast at 8:30 a.m. (ET) on Thursday, November 6, 2025, to discuss financial results. During the call, management will refer to a slide presentation which will be available on the morning of the call on the "Financial Results" page under the Company's Investor Relations section of its website. Pr

    10/22/25 6:30:00 AM ET
    $STVN
    Medical/Dental Instruments
    Health Care

    Stevanato Group Reports Revenue of €280.0 Million for the Second Quarter of 2025

    Company delivers 8% revenue growth, expanded margins, and maintains fiscal year 2025 guidance Stevanato Group S.p.A. (NYSE:STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, today announced its financial results for the second quarter of 2025. Second Quarter 2025 Highlights (comparisons to prior-year period) Revenue increased 8% to €280.0 million, and high-value solutions represented 42% of total revenue. Gross profit margin increased 210 basis points to 28.1%. Diluted earnings per share were €0.11; adjusted diluted earnings per share were €0.11. Adjusted EBITDA mar

    8/5/25 6:30:00 AM ET
    $STVN
    Medical/Dental Instruments
    Health Care

    $STVN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Stevanato Group S.p.A.

    SC 13G/A - Stevanato Group S.p.A. (0001849853) (Subject)

    11/14/24 4:06:28 PM ET
    $STVN
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13G/A filed by Stevanato Group S.p.A.

    SC 13G/A - Stevanato Group S.p.A. (0001849853) (Subject)

    11/14/24 3:30:56 PM ET
    $STVN
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G filed by Stevanato Group S.p.A.

    SC 13G - Stevanato Group S.p.A. (0001849853) (Subject)

    11/14/24 1:28:35 PM ET
    $STVN
    Medical/Dental Instruments
    Health Care